ALNY Institutional Ownership

ALNYLAM PHARMACEUTICALS INC

Latest close $228.72 as of Aug 5, 2026

Create account to watch
Schedule 13G/13D reports beneficial ownership at an observation date. “Accumulation” or “reduction” is inferred from changes in reported shares when available; it is not a list of individual trades or exact execution prices. Form 13F rows are quarter-end holding context only and do not establish an exact entry date.
Free access includes current parsed ownership filings, reported share changes, and ownership-percentage changes. Filing-specific significance scoring, disclosure-speed analysis, confirmation/divergence signals, and signal alerts require Investor or Pro. The overall institutional consensus preview remains public. Compare plans.
Cross-institution intelligence

Institutional Research

Each institution is compared with its own prior filing, then the latest institution-level directions are compared for breadth.

Latest filing May 14, 2026
Public consensus preview Accumulation leaning 61/100 institutional research score
3 tracked institutions Latest filing May 14, 2026

1 accumulating across 1 comparable institution.

Accumulating1
Unchanged0
Reducing0
Exited0

The overall consensus is public. Detailed holder comparisons, breadth history, ownership charts, and filing-specific signal analysis remain part of Investor and Pro research.

Price context

52-week position is market context and does not change the institutional consensus score.

52-week low$205.87 52-week high$495.55
Latest close $228.72 7.9% through the range

Tracked institutions

Public holder names and filing freshness. Detailed institution-by-institution analysis is locked.

Latest observation Mar 31, 2026
Capital Research Global Investors May 14, 2026 filed
Fidelity / FMR May 6, 2026 filed
BlackRock Legacy Jan 26, 2024 filed
Detailed institutional research

See what is driving the consensus.

Unlock holder-by-holder changes, ownership history, breadth by period, disclosure timing, and filing-specific signal analysis.

Create free account Compare Investor and Pro

A free account adds watchlists and reveals tracker research gauges. Investor or Pro unlocks the detailed research above.

Beneficial ownership filing history

Showing 3 of 4 parsed filing(s) · 1 older require more history access
Holder Observed / filed Reported change Shares Ownership Observation Filing Latest
Capital Research Global Investors CIK0001422848 Mar 31, 2026 observed May 14, 2026 filed · 44d Schedule 13G amendment Reported accumulation 132.6M +3.6M 12.00% 0.00 pts $330.87 $293.45 $228.72
Fidelity / FMR CIK0000315066 Mar 31, 2026 observed May 6, 2026 filed · 36d Schedule 13G amendment Earliest Schedule 13G amendment found 14.6K 12.00% $330.87 $303.00 $228.72
Capital Research Global Investors CIK0001422848 Dec 31, 2024 observed Feb 13, 2025 filed · 44d Initial Schedule 13G Initial Schedule 13G 129.0M 12.00% $235.31 $264.89 $228.72
Explore more institutional activity

Related research

Crawlable links to other securities with similar institutional consensus or recent multi-institution accumulation.

Similar research strength

UCB UNITED COMMUNITY BANKS INC 61/100 Accumulation leaning CHTR CHARTER COMMUNICATIONS INC-A 61/100 Accumulation leaning NTR NUTRIEN LTD 61/100 Accumulation leaning RVLV Revolve Group, Inc. 61/100 Accumulation leaning

Recent multi-institution accumulation

TVTX TRAVERE THERAPEUTICS INC 2 accumulating Aug 6, 2026 PCVX VAXCYTE INC 2 accumulating Aug 6, 2026 VVX V2X INC 2 accumulating Aug 6, 2026 VSEC VSE CORP 3 accumulating Jul 31, 2026